Want to see VCNX full AI Analyst Report?
VCNX Stock Chart & Stats
$0.69
-$0.04(-3.99%)
At close: 4:00 PM EST
$0.69
-$0.04(-3.99%)
Day’s Range― - ―
52-Week Range$0.31 - $1.50
Previous CloseN/A
Volume245.00
Average Volume (3M)1.22K
Market Cap
$3.08M
Enterprise Value$1.65M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume776
30 Day Avg. Volume1,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated PipelineVaccinex’s focus on novel antibodies and semaphorin pathways represents a differentiated R&D platform that targets tumor microenvironment and immune modulation. This strategic specialization can produce durable competitive advantages if clinical programs validate mechanisms and enable licensing or partnerships.
Revenue AccelerationA sharp top-line increase demonstrates advancing programs or commercial/partner revenue traction versus prior years. Sustained revenue growth from a low base can materially improve operating leverage over months and help absorb fixed R&D costs as programs mature or partnerships scale.
Very High Gross MarginHigh gross margins suggest product or service economics that can support profitability as revenue scales. For a biotech, strong gross margin implies limited cost of goods and potential for operating leverage, meaning incremental revenue could translate efficiently into improved operating results over time.
Bears Say
Persistent Net LossesConsistent multi-year net losses create an enduring drain on resources and raise the likelihood of additional financing. Continued unprofitability limits internal funding for R&D and commercialization, risks dilution from capital raises, and constrains long-term financial flexibility if losses persist.
Negative Equity And Rising DebtNegative equity and materially increased debt indicate a stressed capital structure and heightened refinancing risk. This weak balance sheet reduces strategic optionality, can increase borrowing costs or restrictive covenants, and raises solvency concerns if operating losses continue.
Ongoing Cash BurnSustained negative operating and free cash flow, despite improvement versus 2024, creates a persistent funding need. Continued cash burn forces dependence on external capital, risks program delays if funding tightens, and makes long-term planning sensitive to financing market conditions.
Vaccinex News
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.31 and its highest was $1.50 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $3.08M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Nov 16, 2026 which is in 118 days.
How were Vaccinex Inc’s earnings last quarter?
Currently, no data Available
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaccinex Inc
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
6.13% Other Institutional Investors
93.87% Public Companies and
Individual Investors